Evidence map›Paper›PMID 42410680›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Neuropathology-specific language features in primary progressive aphasia.

Jane Stocks, Elena Barbieri, Michelle Anne Los, Cynthia K Thompson, Tamar Gefen, Changiz Geula, M-Marsel Mesulam, Sandra Weintraub

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jane StocksDepartment of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-1778-330X
Elena BarbieriMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Michelle Anne LosMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Cynthia K ThompsonDepartment of Communication Sciences and Disorders, Northwestern University, Evanston, Illinois, USA.
Tamar GefenDepartment of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Changiz GeulaMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
M-Marsel MesulamMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Sandra WeintraubDepartment of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Funding

Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 1996 to 2020
$28.9M
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SANDRA WEINTRAUB · 2021 to 2026
$26.3M
ASYMMETRIC NEURODEGENERATION AND LANGUAGE IN PRIMARY PROGRESSIVE APHASIAR01AG077444 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MAREK-MARSEL M MESULAM, EMILY J ROGALSKI · 2022 to 2026
$10.4M
Clinical, Neuroanatomic, and Pathologic Signatures of FTLD-tau in Dementia Phenotypes - Diversity Supplement (Antwan Howard)R01AG062566 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GEFEN, TAMAR D · 2020 to 2024
$2.1M
NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG072977NIA NIH HHS R01 AG062566NIA NIH HHS R01 AG077444NIH HHS 5R01AG077444NIH HHS P30AG013854NIH HHS P30AG072977NIH HHS R01AG062566the Florane and Jerome Rosenstone Fellowshipthe Karen Toffler Charitable Trust
6 · The paper itself

Abstract

introductionPrimary Progressive Aphasia (PPA) clinical syndromes do not align consistently with underlying pathology. This study aimed to identify language markers for specific neuropathologies using both standard clinical tests and narrative speech analysis.

methodsWe analyzed data from 82 autopsy-confirmed PPA cases, including Alzheimer's disease (AD), transactive DNA-binding protein 43 (TDP-43) type C (TDP-C), Pick's disease, and 4R-tauopathies (progressive supranuclear palsy/ cortico-basal degeneration (PSP/CBD). Linear mixed-effects regression was used to analyze performance on standardized aphasia tests and narrative speech variables.

resultsTDP-C showed severe semantic deficits but high fluency, while AD was distinguished by impaired repetition. Narrative analysis differentiated 4R-Tauopathies: CBD patients demonstrated significantly poorer syntax and irregular verb inflection than PSP or Pick's, whereas PSP showed the lowest fluency. DISCUSSION: While standard tests effectively capture lexical-semantic features in AD and TDP-C, narrative measures reveal subtle grammatical and fluency differences critical for distinguishing specific tauopathies. This study outlines a more robust approach for predicting underlying pathology in PPA.

Indexed as

Aphasia, Primary ProgressiveLanguageAgedAged, 80 and overAlzheimer DiseaseBrainCorticobasal DegenerationFemaleHumansMaleMiddle AgedNeuropsychological TestsPick Disease of the BrainSupranuclear Palsy, ProgressiveTauopathies4R‐tauopathiesAlzheimer's diseasedifferential diagnosisfluencylanguagelexical‐semanticsmorphologyneuropsychologyPick's diseasePrimary Progressive AphasiaspeechsyntaxTDP‐43 type C

Identifiers

PMID42410680
PMCPMC13337532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.